Literature DB >> 18757693

Treating pulmonary hypertension in COPD: where do we start?

M M Hoeper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18757693     DOI： 10.1183/09031936.00091908

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  3 in total

1.  Adenosine A2B receptor and hyaluronan modulate pulmonary hypertension associated with chronic obstructive pulmonary disease.

Authors:  Harry Karmouty-Quintana; Tingting Weng; Luis J Garcia-Morales; Ning-Yuan Chen; Mesias Pedroza; Hongyan Zhong; Jose G Molina; Raquel Bunge; Brian A Bruckner; Yang Xia; Richard A Johnston; Matthias Loebe; Dewan Zeng; Harish Seethamraju; Luiz Belardinelli; Michael R Blackburn
Journal:  Am J Respir Cell Mol Biol       Date:  2013-12       Impact factor: 6.914

2.  Imbalanced prostanoid release mediates cigarette smoke-induced human pulmonary artery cell proliferation.

Authors:  Abdullah A Alqarni; Oliver J Brand; Alice Pasini; Mushabbab Alahmari; Abdulrhman Alghamdi; Linhua Pang
Journal:  Respir Res       Date:  2022-05-28

3.  Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension.

Authors:  Lan Wang; Yuan-Zhe Jin; Qin-Hua Zhao; Rong Jiang; Wen-Hui Wu; Su-Gang Gong; Jing He; Jin-Ming Liu; Zhi-Cheng Jing
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-11-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.